Cencora management check

COR · Health Care · Health Care Distributors · CEO Robert P. Mauch

Filings as of

66
Management score, ranked 233rd of 487Strongest: owner returns. Weakest: stable leadership. See the best and worst run in Health Care →

3 good · 2 to watch · 1 flagged, across the seven questions below.

  • Good

    Have owners done well?

    Beat its chosen peers

    $100 invested at the start of fiscal 2021 grew to $342, against $144 for the peer group the company picked itself.

  • Watch

    Does pay follow performance?

    Pay only loosely tracked returns

    Over 5 years, the CEO's pay actually paid (equity valued at the share price) had a correlation of 0.21 with shareholder return. 1 means pay moved in step; below 0, the opposite way.

  • Watch

    What does the CEO cost owners?

    1.2% of net income

    $18.3m of reported pay in fiscal 2025, against $1.6bn of net income.

  • n/a

    Do they own the stock?

    No recent CEO filing

    Both: 2 buyers ($2.3m) and 3 sellers ($4.7m) in six months. 2 of 4 sales ran on pre-arranged 10b5-1 plans.

  • Good

    Are owners being diluted?

    Share count shrinking

    Diluted shares changed -2.3% a year over the last three fiscal years. Stock-based pay was 0.0% of revenue in the latest year.

  • Flag

    Is leadership stable?

    2 CEOs in the pay table

    CEOs in the pay table: Steven H. Collis, Robert P. Mauch. 15 filings under 8-K item 5.02 (officers or directors leaving or joining, or new pay arrangements) in the last 3 years.

  • Good

    Are the books clean?

    No red flags on file

    No restatements, auditor changes or late filings since 2021.

Against the S&P 500

Each check's score (0–100) and how it compares: the share of ranked S&P 500 companies it matches or beats, and the median in Health Care.

CheckScoreAt or aboveSector median
Owner returns100100%26
Pay for performance6019%85
CEO cost4545%44
Skin in the game——46
Dilution7971%68
Stable leadership107%70
Clean books100100%100

Closest peers

Others in Health Care Distributors, by management score. Cencora is 27th of 60 in its sector.

  1. 45CAHCardinal Health81
  2. 150MCKMcKesson72
  3. 219DGXQuest Diagnostics67
  4. 233CORCencora66
  5. 246RVTYRevvity64
  6. 419HSICHenry Schein50

Pay versus performance

From the proxy statement filed January 22, 2026. "Actually paid" values stock awards at the share price, so it rises and falls with the stock.

CEO pay by fiscal yearAs reported Actually paid
$0$30.7m$61.4m20212022202320242025
What $100 becameCompany Peer group
$10020212022202320242025$342
Fiscal yearCEOCEO payActually paidOther executives (avg)$100 becamePeersNet income
2025Robert P. Mauch$18.3m$33.9m$6.1m$342$144$1.6bn
2024Steven H. Collis$18.5m$61.4m$7.8m$244$156$1.5bn
2023Steven H. Collis$17.5m$33.8m$5.1m$193$128$1.7bn
2022Steven H. Collis$16.7m$26.1m$4.4m$144$118$1.7bn
2021Steven H. Collis$14.9m$39.8m$4.6m$125$123$1.5bn

The board says pay is tied most to Adjusted EPS. Its other key measures: Adjusted Operating Income*, Adjusted EPS*, Adjusted Free Cash Flow*, Adjusted ROIC*.

Insiders and the CEO's stake

Both: 2 buyers ($2.3m) and 3 sellers ($4.7m) in six months. 2 of 4 sales ran on pre-arranged 10b5-1 plans.

  • BoughtDermot Mark DurcanDirector$2.2mJun 18, 2026
  • BoughtLauren M TylerDirector$149kJun 22, 2026
  • SoldElizabeth S CampbellExecutive Vice President$3.7mAug 24, 2026
  • SoldLazarus KrikorianSVP & Chief Accounting Officer · 10b5-1 plan$620kOct 1, 2026

Leadership and governance on file

Latest shareholder vote results: Mar 6, 2026, including the say-on-pay vote.

Where the money went

Over 2021–2025: $5.7bn returned to owners in buybacks and dividends, 71% of net income, and $613.6m of pay in stock.

Fiscal year20212022202320242025
Revenue$214.0bn$238.6bn$262.2bn$294.0bn$321.3bn
Net income$1.5bn$1.7bn$1.7bn$1.5bn$1.6bn
Stock-based pay$99.6m$93.4m$124.6m$148.0m$148.0m
Buybacks$82.2m$483.7m$1.2bn$1.5bn$435.5m
Dividends$366.6m$391.7m$398.8m$416.2m$437.1m
Diluted shares208m211m205m200m195m

Educational only, not investment advice. Figures are as filed with the SEC: pay from the proxy's pay-versus-performance table, capital allocation from 10-K XBRL data, insider trades from Form 4s over the last six months, events from the last 5 years of filings. The peer group is the one the company chose. See the method.